Capricor Therapeutics (CAPR) Says ALLSTAR Phase II Trial of CAP-1002 Showed Low Probability of Achieving Statistically-Significant Difference

May 12, 2017 6:45 AM

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that a pre-specified administrative interim analysis performed on six-month follow-up data from the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found